Prostate cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PSMA 269
• AR 15
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• PI3K 2
• STAT3 0
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• AMPK 0
• CDK4/6 4
• HER2 6
• MAPK 0
• NRF2 0
• FAK 0
• YAP 0
• PPAR 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• HDAC 0
• IL-15 4
• METTL3 1
• ATM 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 31+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

  NCT03442556· University of Washington· Updated 26 Aug 2026

  “Terminated due to insufficient funding”Registry text, quoted unchanged. Source

• Terminated

  Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

  NCT02769962· National Cancer Institute (NCI)· Updated 13 Aug 2026

  “Accrual and drug manufacturing and supply were discontinued in 2025.”Registry text, quoted unchanged. Source

• Terminated

  Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

  NCT04030559· University of California, Davis· Updated 14 May 2026

  “PI choice; poor accrual”Registry text, quoted unchanged. Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Updated 6 Nov 2025

  “The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source

• Terminated

  Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

  NCT05501548· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Updated 29 Jan 2025

  “The study was terminated by the IRB due to low accrual,”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

  NCT06065059· Tango Therapeutics, Inc.· Updated 13 Aug 2024

  “Terminated due to safety”Registry text, quoted unchanged. Source

• Withdrawn

  Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Updated 2 May 2024

  “No subjects enrolled in the study”Registry text, quoted unchanged. Source

• Terminated

  ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

  NCT04267939· Bayer· Updated 21 Dec 2023

  “There was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore Sponsor has decided to terminate the investigation.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Pfizer· Source

• [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

  NCT07723651· Washington University School of Medicine· Source

• Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  NCT07590934· AstraZeneca· Source

• A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

  NCT06844383· Prostate Cancer Clinical Trials Consortium· Source

• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

  NCT02769962· National Cancer Institute (NCI)· Source

• A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

  NCT04194554· University of Michigan Rogel Cancer Center· Source

• A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· pharmaand GmbH· Source

• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 41
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 152
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 31
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 124
• Magnetic Resonance Imaging 460
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 274
• Genome-Wide Association Study 60

• Identification of ageing-related genes in prostate cancer with type 2 Diabetes using machine learning: a multi-omics study focusing on SOX4, PRNP, and FOXO4.

  Artif Cells Nanomed Biotechnol, Oct 2026

• Development and External Validation of a Machine Learning-Derived Risk Stratification Score for Metastatic Castration-Resistant Prostate Cancer.

  JCO Clin Cancer Inform, Oct 2026

• Potential Molecular Links Between Triclosan Exposure and Prostate Cancer: An Integrative Computational Analysis.

  Int J Mol Sci, Oct 2026

• Untranslated Region-FNex: An Integrative Multimodal Framework for Functional Untranslated Region Variant Prioritization.

  J Chem Inf Model, Oct 2026

• Interpretable Machine Learning Prognostic Model Integrating Inflammatory-Nutritional Biomarkers for Post-Prostatectomy Biochemical Recurrence: Development, Internal Validation, and Translational Target Exploration.

  Curr Oncol, Oct 2026

• Predicting miRNA-Disease Associations Based on Contrastive Learning of Linear and Nonlinear Features.

  Genes (Basel), Oct 2026

• Explainable Machine Learning-Based Prediction of Progression-Free Survival in Prostate Cancer: Retrospective Cohort Study.

  JMIR Cancer, Oct 2026

• General versus site specific quantile random forest models for virtual patient-specific quality assurance of VMAT plans.

  J Appl Clin Med Phys, Oct 2026

• Development and external validation of an explainable machine-learning model for early complications following robot-assisted radical prostatectomy: a multicenter study.

  J Robot Surg, Oct 2026

• Development and evaluation of a combined machine learning model for the prediction of acute GU toxicity in prostate cancer radiotherapy.

  Phys Med, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.